2025 25099_14th Annual Pancreatic Cancer Symposium Evaluation

1 Start 2 Complete

Overall Symposium

Please rate the 14th Annual Pancreatic Cancer Symposium on the following:

	Strongly Agree	Agree	Neither Agree nor Disagree	Disagree	Strongly Disagree
Overall, the symposium met my expectations.	Overall, the symposium met my expectations. - Strongly Agree	Overall, the symposium met my expectations. - Agree	Overall, the symposium met my expectations. - Neither Agree nor Disagree	Overall, the symposium met my expectations. - Disagree	Overall, the symposium met my expectations. - Strongly Disagree
The content of the symposium met my expectations.	The content of the symposium met my expectations. - Strongly Agree	The content of the symposium met my expectations. - Agree	The content of the symposium met my expectations. - Neither Agree nor Disagree	The content of the symposium met my expectations. - Disagree	The content of the symposium met my expectations. - Strongly Disagree
The format was conducive to the meeting.	The format was conducive to the meeting. - Strongly Agree	The format was conducive to the meeting. - Agree	The format was conducive to the meeting. - Neither Agree nor Disagree	The format was conducive to the meeting. - Disagree	The format was conducive to the meeting. - Strongly Disagree
The location of the meeting was convenient.	The location of the meeting was convenient. - Strongly Agree	The location of the meeting was convenient. - Agree	The location of the meeting was convenient. - Neither Agree nor Disagree	The location of the meeting was convenient. - Disagree	The location of the meeting was convenient. - Strongly Disagree

Sessions

Please evaluate the content of each of the following sessions/discussions

	Extremely Satisfied	Satisfied	Neither Satisfied nor Dissatisfied	Dissatisfied	Did Not Attend
"ASCO GI Update" - Mandana Kamgar, MD	"ASCO GI Update" - Mandana Kamgar, MD - Extremely Satisfied	"ASCO GI Update" - Mandana Kamgar, MD - Satisfied	"ASCO GI Update" - Mandana Kamgar, MD - Neither Satisfied nor Dissatisfied	"ASCO GI Update" - Mandana Kamgar, MD - Dissatisfied	"ASCO GI Update" - Mandana Kamgar, MD - Did Not Attend
"KRAS inhibition in pancreatic cancer: What we know now and a look to the future" - Mark O'Hara, MD	"KRAS inhibition in pancreatic cancer: What we know now and a look to the future" - Mark O'Hara, MD - Extremely Satisfied	"KRAS inhibition in pancreatic cancer: What we know now and a look to the future" - Mark O'Hara, MD - Satisfied	"KRAS inhibition in pancreatic cancer: What we know now and a look to the future" - Mark O'Hara, MD - Neither Satisfied nor Dissatisfied	"KRAS inhibition in pancreatic cancer: What we know now and a look to the future" - Mark O'Hara, MD - Dissatisfied	"KRAS inhibition in pancreatic cancer: What we know now and a look to the future" - Mark O'Hara, MD - Did Not Attend
"Systemic therapy and sequence of therapy for NET" - Alexandria T. Phan, MD	"Systemic therapy and sequence of therapy for NET" - Alexandria T. Phan, MD - Extremely Satisfied	"Systemic therapy and sequence of therapy for NET" - Alexandria T. Phan, MD - Satisfied	"Systemic therapy and sequence of therapy for NET" - Alexandria T. Phan, MD - Neither Satisfied nor Dissatisfied	"Systemic therapy and sequence of therapy for NET" - Alexandria T. Phan, MD - Dissatisfied	"Systemic therapy and sequence of therapy for NET" - Alexandria T. Phan, MD - Did Not Attend
"Surgical Debulking of PNET: when, how and how much?" - Callisia N. Clarke, MD	"Surgical Debulking of PNET: when, how and how much?" - Callisia N. Clarke, MD - Extremely Satisfied	"Surgical Debulking of PNET: when, how and how much?" - Callisia N. Clarke, MD - Satisfied	"Surgical Debulking of PNET: when, how and how much?" - Callisia N. Clarke, MD - Neither Satisfied nor Dissatisfied	"Surgical Debulking of PNET: when, how and how much?" - Callisia N. Clarke, MD - Dissatisfied	"Surgical Debulking of PNET: when, how and how much?" - Callisia N. Clarke, MD - Did Not Attend
"Proton therapy for pancreatic and upper GI cancers, improved dosimetry is just the beginning" - William A. Hall, MD	"Proton therapy for pancreatic and upper GI cancers, improved dosimetry is just the beginning" - William A. Hall, MD - Extremely Satisfied	"Proton therapy for pancreatic and upper GI cancers, improved dosimetry is just the beginning" - William A. Hall, MD - Satisfied	"Proton therapy for pancreatic and upper GI cancers, improved dosimetry is just the beginning" - William A. Hall, MD - Neither Satisfied nor Dissatisfied	"Proton therapy for pancreatic and upper GI cancers, improved dosimetry is just the beginning" - William A. Hall, MD - Dissatisfied	"Proton therapy for pancreatic and upper GI cancers, improved dosimetry is just the beginning" - William A. Hall, MD - Did Not Attend
Leveraging human tissue based research to understand heterogeneity of behavior and response in pancreatic adenocarcinoma" - Y. David Seo, MD	Leveraging human tissue based research to understand heterogeneity of behavior and response in pancreatic adenocarcinoma" - Y. David Seo, MD - Extremely Satisfied	Leveraging human tissue based research to understand heterogeneity of behavior and response in pancreatic adenocarcinoma" - Y. David Seo, MD - Satisfied	Leveraging human tissue based research to understand heterogeneity of behavior and response in pancreatic adenocarcinoma" - Y. David Seo, MD - Neither Satisfied nor Dissatisfied	Leveraging human tissue based research to understand heterogeneity of behavior and response in pancreatic adenocarcinoma" - Y. David Seo, MD - Dissatisfied	Leveraging human tissue based research to understand heterogeneity of behavior and response in pancreatic adenocarcinoma" - Y. David Seo, MD - Did Not Attend
"Preventing disease progression through dismantling pro-metastatic inflammatory processes" - Nikki Lytle, PhD	"Preventing disease progression through dismantling pro-metastatic inflammatory processes" - Nikki Lytle, PhD - Extremely Satisfied	"Preventing disease progression through dismantling pro-metastatic inflammatory processes" - Nikki Lytle, PhD - Satisfied	"Preventing disease progression through dismantling pro-metastatic inflammatory processes" - Nikki Lytle, PhD - Neither Satisfied nor Dissatisfied	"Preventing disease progression through dismantling pro-metastatic inflammatory processes" - Nikki Lytle, PhD - Dissatisfied	"Preventing disease progression through dismantling pro-metastatic inflammatory processes" - Nikki Lytle, PhD - Did Not Attend
"Neoadjuvant treatment of pancreatic cancer - the PREOPANC trials" - Bas Groot Koerkamp, MD, PhD	"Neoadjuvant treatment of pancreatic cancer - the PREOPANC trials" - Bas Groot Koerkamp, MD, PhD - Extremely Satisfied	"Neoadjuvant treatment of pancreatic cancer - the PREOPANC trials" - Bas Groot Koerkamp, MD, PhD - Satisfied	"Neoadjuvant treatment of pancreatic cancer - the PREOPANC trials" - Bas Groot Koerkamp, MD, PhD - Neither Satisfied nor Dissatisfied	"Neoadjuvant treatment of pancreatic cancer - the PREOPANC trials" - Bas Groot Koerkamp, MD, PhD - Dissatisfied	"Neoadjuvant treatment of pancreatic cancer - the PREOPANC trials" - Bas Groot Koerkamp, MD, PhD - Did Not Attend
Case Discussion - Kathleen K. Christians, MD & Douglas B. Evans, MD	Case Discussion - Kathleen K. Christians, MD & Douglas B. Evans, MD - Extremely Satisfied	Case Discussion - Kathleen K. Christians, MD & Douglas B. Evans, MD - Satisfied	Case Discussion - Kathleen K. Christians, MD & Douglas B. Evans, MD - Neither Satisfied nor Dissatisfied	Case Discussion - Kathleen K. Christians, MD & Douglas B. Evans, MD - Dissatisfied	Case Discussion - Kathleen K. Christians, MD & Douglas B. Evans, MD - Did Not Attend

Participation

I attended this symposium for the opportunity to (Check all that apply):

Network with other medical professionals

Continue my own professional development

Present my scientific/academic work

Other: (Please specify)

Participation Other: (Please specify)

Attend Again

I would attend another MCW Pancreatic Cancer Symposium

Yes

Maybe (Please specify)

Attend Again Maybe (Please specify)

Future Symposium

I think that future symposiums should include:

Commercial Bias

Was the symposium free of commercial bias?

Yes, the content presented was free of commercial bias.

No, there was commercial bias at the symposium. (Please explain)

Commercial Bias No, there was commercial bias at the symposium. (Please explain)

Comments

Please provide any additional comments you may have regarding the symposium:

Leave this field blank

Medical College of Wisconsin

Office of Continuing and Professional Education

2025 25099_14th Annual Pancreatic Cancer Symposium Evaluation

You are here

2025 25099_14th Annual Pancreatic Cancer Symposium Evaluation